arrayMap 2014: an updated cancer genome resource. by Cai, H. et al.
Published online 26 November 2014 Nucleic Acids Research, 2015, Vol. 43, Database issue D825–D830
doi: 10.1093/nar/gku1123
arrayMap 2014: an updated cancer genome resource
Haoyang Cai1,2,3,*, Saumya Gupta1,2, Prisni Rath2,4, Ni Ai1,2 and Michael Baudis1,2,*
1Institute of Molecular Life Sciences, University of Zurich, 8057 Zurich, Switzerland, 2Swiss Institute of Bioinformatics,
8057 Zurich, Switzerland, 3Center of Growth, Metabolism, and Aging, Key Laboratory of Bio-Resources and
Eco-Environment, College of Life Sciences, Sichuan University, Chengdu 610064, Sichuan, China and 4Centre for
Integrative Genomics, University of Lausanne, 1015 Lausanne, Switzerland
Received September 1, 2014; Revised October 19, 2014; Accepted October 25, 2014
ABSTRACT
Somatic copy number aberrations (CNA) represent a
mutation type encountered in the majority of cancer
genomes. Here, we present the 2014 edition of ar-
rayMap (http://www.arraymap.org), a publicly acces-
sible collection of pre-processed oncogenomic array
data sets and CNA profiles, representing a vast range
of human malignancies. Since the initial release, we
have enhanced this resource both in content and es-
pecially with regard to data mining support. The 2014
release of arrayMap contains more than 64 000 ge-
nomic array data sets, representing about 250 tumor
diagnoses. Data sets included in arrayMap have been
assembled from public repositories as well as ad-
ditional resources, and integrated by applying cus-
tom processing pipelines. Online tools have been
upgraded for a more flexible array data visualization,
including options for processing user provided, non-
public data sets. Data integration has been improved
by mapping to multiple editions of the human refer-
ence genome, with the majority of the data now be-
ing available for the UCSC hg18 as well as GRCh37
versions. The large amount of tumor CNA data in
arrayMap can be freely downloaded by users to pro-
mote data mining projects, and to explore special
events such as chromothripsis-like genome patterns.
INTRODUCTION
Somatic genomic alterations refer to DNA sequence
changes that are acquired during an individual’s life-
time in the body’s tissues (1,2). The type of unbal-
anced structural alterations which are called copy number
aberrations/alterations (CNAs) are important subclasses of
somatic DNA changes, including duplication, multi-copy
amplification as well as homo- or heterozygous deletions of
chromosomal segments (3). These frequently complex aber-
rations have been found in nearly all human tumor types,
with regions spanning from several dozens of nucleotide
bases to whole chromosomes (4–6). CNAs contribute to the
initiation and progression of human malignancies by acti-
vating oncogenes, silencing tumor suppressor genes or dis-
turbing gene expression through the involvement of regula-
tory elements (7,8). In the last two decades, array compara-
tive genomic hybridization (aCGH) technologies have revo-
lutionized cancer genome research by allowing the genome-
wide detection of CNAs with high spatial resolution (9,10)
(we use the term ‘aCGH’ both for dual color experiments
as well as for single color oligonucleotide arrays that rely
on external reference data sets).
The tens of thousands of tumor samples profiled by
genomic arrays and deposited in public repositories al-
low researchers to identify patterns of non-random CNA
events related to different cancer types, and to pinpoint in-
volvement of specific cancer genes (6,11,12). A number of
databases providing curated CNA data are available online,
such as CaSNP (13), CanGEM (14) and Progenetix (15).
These resources typically focus on particular data type, are
derived from a restricted range of array platforms or do not
contain probe-level data representation.
The public version of arrayMap was launched in 2012
(16) as a reference resource for array based genome data
sets of copy number imbalances in human malignancies. It
presents pre-processed cancer genome data, mainly derived
from processed NCBI Gene Expression Omnibus (GEO)
(17) and EBIArrayExpress (18) data sets, but also including
user provided and publication derived data, and provides
online tools to perform basic data analysis and visualiza-
tion. Users can freely download probe-level and segmented
genomic array data from the web site. Typical uses of ar-
rayMap data include investigation of potential markers for
cancer diagnosis and therapy; identification of particular
low incidence events (e.g. chromothripsis-like patterns) (19–
21); large-scale data mining, such as construction of specific
cancer type CNA patterns, and comparison of arrayMap
data with users’ pre-publication data sets. Here, we summa-
rize new developments in arrayMap content and utilities,
which aim to increase data coverage and accuracy and im-
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Figure 1. Distribution of arrays archived in arrayMap according to plat-
form types and resolution. The usage of higher resolution platforms in-
creased dramatically in recent years, with a concomitant decrease of espe-
cially low resolution BAC/P1 platforms.
portantly facilitate the use of this resource through a docu-
mented data interface.
DATA CONTENT UPDATES
Data growth
At the time of its launch, the original arrayMap edition con-
tained about 40 000 arrays from 260 different platforms,
representing 224 cancer diagnoses as defined in the Inter-
national Classification of Diseases in Oncology (ICD-O 3)
(22). For the 2014 edition, the absolute number of data
sets has been increased to 64 814 genomic copy number ar-
rays from 985 experimental series, involving 343 array plat-
forms. The primary data had been published in more than
700 original publications, and now represents 252 ICD-O
cancer entities (Table 1). Over time, relatively low resolu-
tion array platforms are replaced by higher resolution or
multi-function platforms. At themoment, the platformwith
the highest probe numbers in arrayMap contains about 2.2
million individual probes. In line with this trend, ∼60% of
the added arrays contain more than 250K probes. Since the
data generated by high resolution arrays increased rapidly
in recent years, we anticipate that this growth trendwill con-
tinue (Figure 1) with special impact on the detection of focal
genomic imbalances.
In this update, most novel samples were integrated from
theNCBIGEO repository (17). Ourmain data selection cri-
teria are that the data must be derived from human tumor
samples and, where available, related germline DNA refer-
ence samples hybridized on single or dual color genomic
array platforms. While primarily focusing on arrays with
at least full autosomal coverage, we also integrated several
studies with limited genome coverage which may provide
useful information regarding gene specific CNAs in certain
cancer types. In general, we used the formerly described
pipeline (16) to re-process different data types. Briefly, for
Affymetrix CEL files, we applied the aroma.affymetrix R
package with the CRMAv.2 method (23) but utilized in-
house scripts for data sets with available normalized probe
intensity values. All probe signals were converted to log2
values, and Circular Binary Segmentation algorithm (24)
was used for segmentation. For each array, empirical thresh-
olds were assigned to call genomic gains and losses.
At the time of writing, data in arrayMap represent
252 ICD-O morphology codes. The largest of these are
with 9551 samples ‘adenocarcinoma, NOS’ (8140/3; con-
tains samples from e.g. prostate, gastric, colorectal and
lung adenocarcinomas) and with 8188 samples ‘inva-
sive carcinoma of no special type’ (8500/3; default his-
tology for the majority of breast cancer samples; Fig-
ure 2). On the other end, 25 histologies are represented
through a single array, among them e.g. ‘giant cell sar-
coma’ and ‘islet cell carcinoma’. The complete list of
ICD-O histologies is available through the supplements or
can be accessed through the data API (application pro-
gram interface; see below) at http://arraymap.org/api/?db=
arraymap&api out=icdmlist&icdm m=0,8,9. Among the
clinical entities, breast cancers constitute by far the largest
category (8837 arrays) followed by non-small cell lung carci-
nomas (4112 arrays), acute myeloid leukemias (3641 arrays)
and colorectal carcinomas (3047 arrays; Supplementary Ta-
ble 2). The complete list is provided as supplement, or can
be generated through calling ‘http://arraymap.org/api/?db=
arraymap&api out=cgrouplist&icdm m=0,8,9’.
Compared to managed large-scale projects with frequent
focus on a few predominant cancer types, the assembly of
data from hundreds of individual studies has an inherent
advantage in representing the heterogeneous landscape of
human malignancies. As an example, when matching the
arrayMap data to the content of the TCGA / ‘Pan-cancer
project’ (25,26), one can observe that the 12 tumor types on
which the ‘Pan-Cancer’ study has focused so far correspond
to about half of the sample content in arrayMap (Table
2). While the efforts of the leading TCGA and ICGC (27)
projects aim at a detailed multi-level description of molec-
ular aberrations and their biological impact on cancer pro-
gression, the proportion of arrayMap samples from cancers
not represented in those studies should serve as a reminder
of the large number of ‘rare’ tumor types encountered in
oncological practice, and the gap in our understanding of
their molecular mechanisms. In our opinion, the arrayMap
resource can prove especially useful in promoting oncoge-
nomic datamining projects aimed at identifying exceptional
tumor biologies.
Besides the focus on cancer samples, the new edition
of arrayMap also contains normal tissue samples that
were used as controls in cancer profiling experiments. The
amount of high resolution data from more than 8000 nor-
mal samples now allows for the creation of a matched num-
ber variation track, without relying on external resources
(28–30) (Supplementary Figure S1). These data can be used
to perform robust CNA data analysis, e.g. through pro-
viding a veto filter for the evaluation of focal (< 3–5 Mb)
CNA events, which usually cannot be distinguished from
germline variations without matched non-tumor samples.
Genome reference assembly mapping
In the first release of arrayMap, all genomic mapping
information for probe positions and derived CNA seg-
ments was converted to the human genome assemblyUCSC
hg18 (NCBI Build 36.1) (31, http://www.ncbi.nlm.nih.gov/
projects/genome/assembly/grc/human/data/), to allow for
the integration of the different platform types and exper-
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Table 1. arrayMap content increase (as of 31 August 2014) compared to the initial release
Database content Number of entries 2012 Number of entries 2014
Arrays ∼ 40 000 64 814
Series 533 985
Platforms 260 343
ICD-O cancer types 224 252
Publications 638 716
Patients 15 634 23 713
Figure 2. Frequency of copy number gains (up, yellow) and losses (down, blue), derived from 7497 breast cancer arrays (here limited to ICD 8500/3), as
represented in the arrayMap database. For each of the included arrays, experiment specific CNA data can be accessed individually.
Table 2. The proportions of TCGA ‘Pan-Cancer’ tumor diagnoses in arrayMap
Tumor types Array numbers Percentage
Breast carcinoma 8837 15.8%
Lung adenocarcinoma 3464 6.2%
Colon adenocarcinoma 3085 5.5%
Lymphoblastic acute myeloid leukemia 2848 5.1%
Glioblastoma 2517 4.5%
Ovarian carcinoma 2477 4.4%
Kidney renal clear-cell carcinoma 1473 2.6%
Head and neck squamous carcinoma 1423 2.5%
Uterine cervical and endometrial carcinoma 1013 1.8%
Lung squamous carcinoma 839 1.5%
Bladder carcinoma 689 1.2%
Rectal adenocarcinoma 250 0.4%
Other tumor types 27 101 48.5%
imental results. For this goal, a pipeline was generated
to map the genomic positions for the thousands of array
probes to the common ‘Golden Path’ edition. In recent
years, new genome assemblies have been provided, (UCSC
hg19 / GRCh37 and recently UCSC hg20 / GRCh38) with
GRCh37 now frequently being used for referencing ge-
nomic array coordinates. When updating data from hg18
to newer assemblies, the change of probe coordinates may
affect the composition of previously called CNA regions
through un-mapping of some coordinates. To minimize this
problem, for arrays with available probe values we first
remapped all probe positions to GRCh37 using the UCSC
Genome Browser’s liftOver tool with intermediate BED
files (30), and then re-segmented based on the derived probe
positions. Although a few probes failed to be remapped dur-
ing this procedure, the average remapping rate was as high
as 99%. For a subset of e.g. literature derived data sets, seg-
mentation data were processed directly. At the moment we
are planning to migrate the database to the newest GRCh38
assembly.
NEW AND ONGOING DEVELOPMENTS
Web front end and data visualization
Some of the main strengths of the arraymap repository are
the pre-computed visualization of some 10 000 probe-level
genomic array data sets, as well as the graphical represen-
tation of CNA distributions based on curated clinical in-
formation, most notably the samples’ assignment to stan-
dardized diagnostic categories based on theWHO’s ICD-O
3 schema (22). Since the arrayMap resource is based on the
software framework developed for the Progenetix project
(32), the data search and visualization updates reported in
the 2014 Progenetix update (15) apply for the arrayMap
resource, too. For the data selection, these include prede-
fined aggregate data for ICD entities, tumor loci, SEER (33,
http://www.seer.cancer.gov/popdata) categories as well as
‘clinical groups’, referring to samples with a common clin-
ical context (e.g. ‘carcinomas: breast carcinomas’ including
all types of epithelial breast tumors). Another option intro-
duced with the latest Progenetix update and now applied to
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Figure 3. The histogram profile of breast cancer samples focusing on chromosomes 8 and 17 generated by the API, displaying the frequency of copy number
gains (up, yellow) and losses (down, blue). Genomic map positions of two genes were included in the API call, and therefore are labeled at the bottom of
the figure.
arrayMap is the geographic mapping of the included stud-
ies according. In the case of arrayMap, samples are mapped
based on the submitting information fromGEO, with a fall-
back to the corresponding author of the related publication.
While this feature is not as useful as e.g. patient data derived
origin mapping, it nevertheless offers a fast overview about
enters with research activity in the corresponding cancer
types and may support networking activities between re-
search groups. Although the mapping information does not
disclose the samples’ origins, the almost complete lack of
data sets for large swaths of the globe (e.g. Africa, central
Asia, South America) points to unmined cancer genome re-
sources and paucity of research into possible epidemiologi-
cal and environmental factors.
API
The 2014 arrayMap release is the first to provide a REST-
ful data API. The API provides a variety of query and out-
put parameters, with URL formatted (GET) requests re-
turning server side processed data as JSON (Java Script ob-
ject notation) objects, test/tabular data or images suitable
for direct embedding or storage. A detailed and continu-
ously updated documentation can be found online, in the
arrayMap/Progenetix user guide at http://wiki.progenetix.
org.
API Example 1: Sample data as JSON
The following query will return all samples from
ICD-O 3 codes starting with ‘817’ (i.e. hepatocellular
adenomas/carcinomas) from the arrayMap collection:
http://arraymap.org/api/?db=arraymap&api out=
samples&api doctype=json&icdm m=817
API Example 2:
The query will return a gain/loss frequency histogram for
chromosomes 8 and 17, derived from 1000 random samples
of ICD-O 8500/3 (breast carcinoma - ‘invasive carcinoma
of no special type’), in the form of a PNG data stream (Fig-
ure 3):
http://arraymap.org/api/?db=arraymap&markers m=
[MYC]8:128816862-128822853,[ERBB2]17:35104766-
35138441&icdm m=8500/3&randno=1000&api out=
histogram&chr2plot=8,17
API Example 3:
The query will return the number of samples in arrayMap
for ICD-O 8500/3, which have gainCNAs overlapping both
the MYC and ERBB2 loci:
http://arraymap.org/api/?db=arraymap&locus m=8:
128816862-128822853:1,17:35104766-35138441:
1&icdm m=8500/3&;api out=count
API: R
With the ability to access the status matrix directly, one eas-
ily can import the data into an R data frame:
pgframe <- read.table(url(‘http://arraymap.org/api/
?icdm m=814&db=arraymap&api out=matrix’), header =
T, sep = ‘\t’, na = ‘NA’)
For the segment file, the same applies with
‘output=segments’:
segtable <- read.table(url(‘http://arraymap.org/api/
?text m=sezary&db=arraymap&api out=segments’),
header = T, sep = ‘\t’, na = ‘NA’)
To facilitate R integration of Progenetix/arrayMap data,
we have developed a simple access function ‘pgDataLoader’
which can currently be accessed through GitHub (https:
//github.com/progenetix/pgRpi/). This publication’s supple-
ments include an example use case, describing the genera-
tion of gene specific Kaplan-Meyer survival plots from ar-
rayMap data.
User managed data
In this version of arrayMap, we provide some online sup-
port for the analysis and visualization of user private (i.e.
pre-publication) array data sets. After registration by email,
users are able to use on site storage facilities and recall pre-
vious performed analyses. For example, users can directly
upload and visualize segmentation files, sample tables with
ISCN karyotypes, or JSON files from a previous analysis.
Data subsets from database queries can be reloaded and
used for filtering and replotting. Additionally to these op-
tions, the analysis of raw / pre-processed probe data sets is
supported in collaborative projects. Analysis input here can
be e.g. Affymetrix genotyping array raw data (.CEL files),
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other platforms from log2 value lists, and pre-existing seg-
mentation data.
CONCLUSIONS AND FUTURE PERSPECTIVES
arrayMap is developed to provide a one stop resource of ge-
nomic copy number profiles of human tumors, as well as a
series of online tools for meta-data analysis andmining. Al-
though arrayMap is tightly integrated with and shows some
content overlap with the Progenetix resource (http://www.
progenetix.org), both data collections offer different scopes
and data paradigms (Supplementary Figure S4). In con-
trast to arrayMap, which displays pre-processed but loosely
evaluated experimental array data, Progenetix annotations
are based on sample specific copy number data, from dif-
ferent technologies (chromosomal CGH, genomic arrays,
genome sequencing), were the ‘called’ CNA had been ei-
ther provided through a publication, or had been assessed
from an active evaluation of the original experimental data.
While the Progenetix resource has an advantage in provid-
ing genomic aberration data for an even wider diagnostic
range than arrayMap (362 versus 252 ICD-O entities), it is
more heterogeneous with respect to included technologies
and spatial resolution of the CNA data sets (e.g. cytoband
based cCGH data) which limits e.g. the detection of rare
focal CNA events.
Since the launch of the resource in 2012, arrayMap un-
derwent a number of quantitative, qualitative and func-
tional improvements, most notably the increase in included
data sets and scope of represented cancer entities, as well
as the addition of programmatic access methods and Pro-
genetix based selection and visualization updates. For the
future expansion of the arrayMap resource, we are eval-
uating the additional inclusion of data sets from multi-
functional platforms (e.g. methylation arrays, mutation-
specific probe sets). Moreover, a robust platform agnostic
quality rating system is under development, and will be in-
tegrated in our database. For the overall data set expansion,
we intend to follow an incremental, dynamic update policy,
with bi-annual reassessments ofmajor data content and fea-
ture changes.
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